Combining Genetic Variants to Improve Risk Prediction for NAFLD and Its Progression to Cirrhosis: A Proof of Concept Study
Table 2
Comparison of PNPLA3 rs738409, TM6SF2 rs58542926, KLF6 rs3750861, SOD2 rs4880, and LPIN1 rs13412852 polymorphisms prevalence, according to study subgroups.
Healthy Subjects
Noncirrhotic NAFLD
NASH cirrhosis
PNPLA3
CC
53 (58.9%)
30 (32.3%)
20 (18.7%)
<0.001
CG
30 (33.3%)
36 (38.7%)
44 (41.1%)
GG
7 (7.8%)
27 (29%)
43 (40.2%)
TM6SF2
CC
79 (87.8%)
74 (79.6%)
79 (73.8%)
0.105
CT
11 (12.2%)
17 (18.3%)
27 (25.2%)
TT
0 (0%)
2 (2.2%)
1 (0.9%)
TM6SF2 dichotomized
CC
79 (87.8%)
74 (79.6%)
79 (73.8%)
0.06
CT/TT
11 (12.2%)
19 (20.4%)
28 (26.2%)
KLF6
CC
79 (87.8%)
80 (86%)
83 (77.6%)
0.224
CT
11 (12.2%)
13 (14%)
23 (21.5%)
TT
0 (0%)
0 (0%)
1 (0.9%)
KLF6 dichotomized
CC
79 (87.8%)
80 (86%)
83 (77.6%)
0.113
CT/TT
11 (12.2%)
13 (14%)
24 (22.4%)
SOD2
CC
26 (28.9%)
20 (21.5%)
30 (28%)
0.795
CT
42 (46.7%)
48 (51.6%)
49 (45.8%)
TT
22 (24.4%)
25 (26.9%)
28 (26.2%)
LPIN1
CC
38 (42.2%)
45 (48.4%)
49 (45.8%)
0.672
CT
41 (45.6%)
37 (39.8%)
50 (46.7%)
TT
11 (12.2%)
11 (11.8%)
8 (7.5%)
Data are shown as absolute number and column percentages. for overall chi-square test. < 0.05 and < 0.001 versus healthy subjects; PNPLA3: patatin-like phospholipase domain containing protein 3; TM6SF2: transmembrane 6 superfamily member 2; KLF6: Kruppel-like factor 6; SOD2: superoxide dismutase 2; LPIN1: lipin 1.